Xencor, Inc. (XNCR) News
Filter XNCR News Items
XNCR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
XNCR News Highlights
- 500 - Internal server error
- Over the past 28 days, the trend for XNCR's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about XNCR are JAZZ and SVRA.
Latest XNCR News From Around the Web
Below are the latest news stories about Xencor Inc that investors may wish to consider to help them evaluate XNCR as an investment opportunity.
Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021MONROVIA, Calif., July 28, 2021--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release second quarter 2021 financial results after the market closes on Wednesday, August 4, 2021. |
Were Hedge Funds Right About Xencor Inc (XNCR)?In this article we will take a look at whether hedge funds think Xencor Inc (NASDAQ:XNCR) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from […] |
Xencor (XNCR) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseXencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Down 10.9% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a TurnaroundXencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder StudySavara (SVRA) is developing its lead pipeline candidate, molgramostim, as a potential treatment for autoimmune pulmonary alveolar proteinosis. |
Jazz Pharma (JAZZ) Gets FDA Approval for Leukemia Drug RylazeJazz Pharma (JAZZ) gets FDA approval for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase. |
Xencor (XNCR) Loses 12.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerXencor (XNCR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer TherapeuticsZacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics |
INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future DilutionPurchase of Xencor Option potentially eliminates approximately 2.1 mill ion shares of INmune future common stock dilution upon execution. |
Omeros (OMER) Announces Preliminary Data on MASP-3 InhibitorOmeros (OMER) announces initial results from a phase I study of OMS906. |